The overall goal of this proposal is to determine whether peptides corresponding to neutralizable contiguous epitopes of the major outer membrane protein (MOMP) of Chlamydia trachomatis are able to confer protection from an infection with this organism. This pathogen is the leading cause of sexually transmitted disease in the Western world and has been implicated as a major contributing factor to infertility. It is also the leading cause of preventable blindness in underdeveloped countries. Due to the morbidity associated with this organism, attempts have been made to vaccinate with the intact organism. From vaccine trials it was concluded that the host immune response contributed to the damaging sequelae associated with a chlamydial infection. More recently in an effort to both circumvent the hypersensitivity reaction as well as increase the number of serovars represented in a vaccine, subunit vaccines have been proposed as a possible solution. Although we realize that both protective B and T cell epitopes will eventually need to be incorporated into an effective vaccine, in this proposal we will focus on epitopes that we have identified and characterized as contiguous and neutralizable to determine whether peptides representing these epitopes can afford protection to the host. We will first focus on serovar E since it is the most common genital isolate of C. trachomatis. Peptides representing neutralizable epitopes will be tested alone, in combination and as a colinear peptide construct for their ability to elicit a protective immune response. The colinear peptides will be used to establish the optimal peptide construction, immunization route, dose, delivery system and if necessary, adjuvant that will elicit a strong mucosal response. Paralleling these efforts we will be working with a murine model of a chlamydial genital infection in order to establish a reproducible model that will be suitable for testing the ability of the immunization parameters established with the peptide constructs to protect or attenuate from a chlamydial infection and the sequelae of infertility. Information gained from this approach should bring us closer to answering the question as to the role of neutralizing antibodies in chlamydial infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI030499-04A1
Application #
2065655
Study Section
Tropical Medicine and Parasitology Study Section (TMP)
Project Start
1991-07-01
Project End
1997-11-30
Budget Start
1994-12-01
Budget End
1995-11-30
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Irvine
Department
Pathology
Type
Schools of Medicine
DUNS #
161202122
City
Irvine
State
CA
Country
United States
Zip Code
92697
Pal, S; Theodor, I; Peterson, E M et al. (2001) Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun 69:6240-7
Pal, S; Peterson, E M; de La Maza, L M (2000) Role of Nramp1 deletion in Chlamydia infection in mice. Infect Immun 68:4831-3
Pal, S; Barnhart, K M; Wei, Q et al. (1999) Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 17:459-65
Peterson, E M; You, J Z; Motin, V et al. (1999) Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar. Vaccine 17:2901-7
Pal, S; Rangel, J; Peterson, E M et al. (1999) Immunogenic and protective ability of the two developmental forms of Chlamydiae in a mouse model of infertility. Vaccine 18:752-61
Motin, V L; de la Maza, L M; Peterson, E M (1999) Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis. Clin Diagn Lab Immunol 6:356-63
Pal, S; Peterson, E M; De La Maza, L M (1999) A murine model for the study of Chlamydia trachomatis genital infections during pregnancy. Infect Immun 67:2607-10
Peterson, E M; de la Maza, L M; Brade, L et al. (1998) Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae. Infect Immun 66:3848-55
Pal, S; Hui, W; Peterson, E M et al. (1998) Factors influencing the induction of infertility in a mouse model of Chlamydia trachomatis ascending genital tract infection. J Med Microbiol 47:599-605
Peterson, E M; Cheng, X; Motin, V L et al. (1997) Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection. Infect Immun 65:2693-9

Showing the most recent 10 out of 25 publications